Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Posters

Search Title by author or title

Artificial iris implantation for pupillary reconstruction: outcomes and complications

Poster Details

First Author: V.de Rojas SPAIN

Co Author(s):    B. Lorente   M. Álvarez   R. Lorente   P. Simón   L. Zurutuza        

Abstract Details

Purpose:

To evaluate the outcomes and complications of artifical iris (AI) implantation for pupillary reconstruction.

Setting:

Department of Ophthalmology Complexo Hospitalario Universitario A Coruña; Complexo Hospitalario Universitario Ourense. Two tertiary referral public hospitals in Spain.

Methods:

Retrospective case series including all patients who underwent AI implantantion using the flexible silicone artifical iris prostphesis (ArtificalIris, Humanoptics AG). Medical records were reviewed and the following data were recorded: age, sex, cause of iris defect, preoperative lens state (phakic, pseudophakic or aphakic), type of AI (with/withour fiber mesh (FM)) pre and postoperative distance corrected visual acuity (CDVA) and intraocular pressure (IOP), complications and patient´s satisfaction.

Results:

9 eyes (9 patients). Follow-up: 22.66±20.41 months. An AI without FM was implanted in the sulcus without sutures (2 cases) and with sutures (1 case), and six AI with FM were sutured to the sclera. Combined procedures: Phacoemulsification (3), secondary IOL implantation (suturing an IOL to the back of AI) (6), penetrating keratoplasty (3). Complete resolution of glare was achieved in all cases. Mean logMAR CDVA improved (from 1.4±0.89 to 0.32±0.34). Complications: leakage and hypotony which was repaired with sutures (1), slight pupil decentration (2), uveitis (1), cystoid macular edema (2), hypertension (6, one of them required Ahmed valve implantation).

Conclusions:

AI implantation provided good cosmetic appearance and resolution of symptoms of glare in all patients. Visual acuity improved in all cases. The main complication was the development of secondary glaucoma.

Financial Disclosure:

None

Back to Poster listing